MorphoSys

OptumRx's 3 recently approved drugs to watch
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
FDA
Kite Pharma
Tecartus
Novartis
Kesimpta
MorphoSys
Monjuvi
OptumRx
Flag link:
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
FDA
Monjuvi
CAR-T
MorphoSys
Incyte
diffuse large B-cell lymphoma
Flag link:
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
MorphoSys
Gilead Sciences
Novartis
CAR-T
tafasitamab
DLBCL
Flag link:
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Incyte
MorphoSys
lymphoma
tafasitamab
Flag link:
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Fierce Biotech
MorphoSys
Galapagos
Novartis
MOR106
atopic dermatitis
Dupixent
Sanofi
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Flag link:
Morphosys to take on CAR-Ts in NHL with promising antibody
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
MorphoSys
Celgene
Revlimid
non-Hodgkin lymphoma
clinical trials
tafasitamab
Flag link:
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Endpoints
CAR-T
MorphoSys
Novartis
Gilead Sciences
tafasitamab
DLBCL
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
daratumumab
patents
Flag link:
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
MorphoSys
Janssen
Genmab
patent lawsuits
patents
Darazalex
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
CP Wire
MorphoSys
Janssen
Genmab
patents
Flag link:
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys
Janssen
Genmab
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
With no partner, MorphoSys drops MOR202 in myeloma
With no partner, MorphoSys drops MOR202 in myeloma
Biopharma Dive
MorphoSys
earnings
anti-CD3 antibody
MOR202
Flag link:
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Yahoo/Bloomberg
Novartis
Galapagos
MorphoSys
MOR106
atopic dermatitis
Flag link:
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
Flag link:
In knockout IPO offerings, MorphoSys and Surface Oncology haul combined $316M in upsized deals
In knockout IPO offerings, MorphoSys and Surface Oncology haul combined $316M in upsized deals
Endpoints
IPOs
MorphoSys
Surface Oncology
NASDAQ
Flag link:
Galapagos peaks as AbbVie hype builds, Shorts target Bavarian, MorphoSys makes GPCR play
Galapagos peaks as AbbVie hype builds, Shorts target Bavarian, MorphoSys makes GPCR play
Fierce Biotech
Galapagos
AbbVie
Bavarian Nordic
Intec Pharma
MorphoSys
Flag link:
MorphoSys: That Celgene-abandoned cancer drug isn't dead yet
MorphoSys: That Celgene-abandoned cancer drug isn't dead yet
Fierce Biotech
MorphoSys
Celgene
MOR202
Flag link:
MorphoSys tanks after Celgene walks away from $818M pact
MorphoSys tanks after Celgene walks away from $818M pact
Fierce Biotech
MorphoSys
Celgene
Multiple Myeloma
Flag link:

Pages